Presenting Companies in the News
Ripple announced a collaboration and option-to-license agreement with AbbVie to develop next-generation therapies for glaucoma management.
Ripple Therapeutics Announces AbbVie Collaboration
Ripple Therapeutics presented at New Horizons Forum in 2023 and 2024.
In September 2024, Ripple announced a collaboration and option-to-license agreement with AbbVie to develop next-generation therapies for glaucoma management. They describe their RTC-620 product in development as “a fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).”
Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. As part of the agreement, Ripple will lead the preclinical development of RTC-620. Upon exercising its option, AbbVie will take the lead in clinical development and commercialization of the implant.
Watch “Medications in Motion – Innovations in Glaucoma Drugs and Drug Delivery” from the 2024 New Horizons Forum:
2025 New Horizons Keynote Announced
The 2025 Drs. Henry and Frederick Sutro Memorial Lecture will be delivered by ophthalmologist, glaucoma specialist, and cutting-edge researcher Carla Siegfried, MD.
Dr. Siegfried is the Jacquelyn E. and Allan E. Kolker, MD Distinguished Professor of Ophthalmology and Vice Chair for Diversity, Equity and Professionalism at Washington University, St. Louis. (Read her Speaker Bio)